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1 ABSTRACT 
Time and space controlled drug delivery still remains a huge challenge in medicine. A novel 
approach that could offer a solution is ultrasound guided drug-delivery. “Ultrasonic drug 
delivery” is often based on the use of small gas bubbles (so-called microbubbles) that 
oscillate and cavitate upon exposure to ultrasound waves. Some microbubbles are FDA 
approved contrast agents for ultrasound imaging and are nowadays widely investigated as 
promising drug carriers. Indeed, it has been observed that upon exposure to ultrasound 
waves, microbubbles may (a) release the encapsulated drugs and (b) simultaneously change 
the structure of the cell membranes in contact with the microbubbles which may facilitate 
drug entrance into cells. This review aims to highlight (a) major factors known so far which 
affect ultrasonic drug delivery (like the structure of the microbubbles, acoustic settings, etc.) 
and (b) summarizes the recent preclinical progress in this field together with a number of 
promising new concepts and applications.  
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2 INTRODUCTION 
Time and space controlled drug delivery remains a holy grail in medicine. It is the wish of 
every scientist or physician to design or have access to a device that only delivers 
therapeutic molecules at a certain target site (e.g. a tumor), leaving healthy tissue unharmed. 
To design such a “magic bullet”, a concept that was first described by Ehrlich in the 
beginning of the 20th
Ultrasound waves are used in medical imaging (e.g. echography). An ultrasound image is 
formed due to the fact that ultrasound waves become reflected by tissues with a density 
different from the surrounding medium [2]. To enhance the contrast of the vasculature or 
other blood containing tissues that do not reflect ultrasound due to their compressibility, 
ultrasound contrast agents (UCAs) can be intravenously injected. UCAs are micron sized (1-
10µm) gas bubbles (microbubbles) with a shell composed out of phospholipids, polymers or 
proteins. These microbubbles are suitable contrast agents because of their interaction with 
the ultrasound wave [3]. A microbubble will start to oscillate in response to the exerted 
cycles of negative and positive pressure. These oscillations itself produce ultrasonic signals 
that can be detected by the ultrasound transducer. Increased pressure will compress the 
microbubbles while negative pressure will induce rarefaction of the bubbles. This process, 
 century, one needs to develop a drug carrier that responds to a 
stimulus applied by an external force or produced by the target tissue itself. Different 
external stimuli such as electromagnetic waves (IR, UV of visible light) or magnetic and 
electrochemical forces can be used to achieve such a trigger, as reviewed by Timko et al [1]. 
Another type of local stimulus can be generated through mechanical waves exerted by 
ultrasound.  
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called cavitation, has been investigated in detail by Bouakaz, Versluis and de Jong [4] using 
high speed light microscopy . 
Cavitation at higher acoustical pressures will induce more violent microbubble oscillations, 
eventually resulting in microbubble destruction (so named ‘inertial cavitation’) [5]. Inertial 
cavitation can be useful in imaging, this to evaluate blood flow abnormalities by means of 
destruction replenishment imaging [6], but is particularly useful in drug delivery as it can 
trigger (a) release of drugs from the microbubbles and (b) uptake of the released drugs into 
the cells whose membranes become temporarily permeablized due to the localized 
mechanical effects related to microbubble implosion [7]. Since ultrasound is only applied at a 
certain location, time- and space-controlled drug delivery may become feasible. 
3 ADVANCES IN MICROBUBBLE DESIGN FOR ULTRASOUND GUIDED DRUG 
DELIVERY 
As schematically represented in Figure 1, four types of ‘microbubble modficiations’ have 
been reported so far for ultrasonic drug delivery: (a) drug-loaded microbubbles; (b) in situ 
formed microbubbles or nanodroplets; (c) acoustically active liposomes (sometimes called 
‘nanobubbles’) and (d) targeted microbubbles.  
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Figure 1: Schematic overview of microbubble modficications reported for ultrasonic drug 
delivery. A) envisions drug-loaded microbubbles releasing their associated payload upon 
insonation, B) shows nanodroplets that are able to extravasate due to Enhanced Permeation 
and Retention (EPR) and form microbubbles after phase transition in situ, C) depicts nano-
sized acoustically active lipospheres in tumor tissue and finally D) shows microbubbles 
associated with a targeting moiety that adhere to target molecules in tissue expressing 
pathophysiologic epitopes. 
3.1  Drug-loaded microbubbles  
Since the 1990’s a number of research groups have attempted to design microbubbles which 
can carry a therapeutic payload. As Figure 2 summarizes, drug delivery from microbubbles 
by ultrasound is an attractive concept for various reasons; (a) using low acoustic pressures 
the drug loaded microbubbles can be visualized, being attractive for ‘image guided drug 
delivery’; (b) many drugs, especially biological drugs like nucleic acids and proteins need to 
be protected from degradation upon administration, which can be accomplished by 
formulating them associated with microbubbles; (c) the loading of the drugs into 
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microbubbles can also prevent their uptake in untreated tissue (i.e. tissue that is not 
exposed to ultrasound) and thus reduce side-effects; (d) upon applying ultrasound, both 
local drug release and cell membrane permeabilization (sonoporation) can occur. 
Figure 2: Schematic overview of the wide potential of  drug-loaded microbubbles. 
A straightforward strategy to load the microbubbles with drugs is associating them with the 
shell or more particularly with its building blocks. Another way of loading is by encapsulating 
the drug into an oil reservoir present in the core of the microbubble. Finally, drugs can also 
be packed into nanoparticles that are subsequently attached to the microbubble’s surface. 
The following section gives an update on the recent progress in the design of drug-loaded 
microbubbles . For a complete overview on drug-loaded microbubbles we refer to lentacker 
et al. and Tinkov et al. [8,9]. 
3.1.1 Loading through electrostatic binding.  
A first strategy to attach therapeutics to the microbubble shell is through electrostatic 
interactions, initially explored to load microbubbles with pDNA. As an example, Frenkel et al 
[10] used albumin-shelled microbubbles as a template for pDNA attachment. A layer-by-
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layer approach can be used to alternately deposit cationic polymers and anionic nucleic acids 
on the microbubble shell, which clearly improves the electrostatic loading of the 
microbubbles with nucleic acids [11]. Sirsi et al [12] recently reported on lipid-shelled 
microbubbles that were covalently coated with PolyEthyleneGlycol-PolyEthyleneImine (PEG-
PEI) copolymers, followed by the electrostatic deposition of pDNA onto such cationically 
charged microbubbles. Ultrasound induced gene expression in tumor tissue was clearly 
observed, being significantly higher than the gene expression in control samples being 
untreated tumors. Similar results were obtained with plasmid conjugated microbubbles, that 
showed a significant increase in gene transfection in smooth muscle cells as well [13]. 
Tinkov et al. [14] described an attractive method to complex Doxorubicin (DOX) onto 
microbubbles using electrostatic interactions. They prepared an anionic microbubble by 
incorporating an anionic phospholipid 1,2-dipalmitoyl-sn-glycero-3-phospho-1'-rac-glycerol 
(DPPG) in the shell which can form a complex with the cationic glycane-group in the DOX 
molecule. This method showed efficient incorporation of DOX into the microbubbles’ shell 
(up to 40 µg DOX per ml microbubble dispersion); tumor cell destruction was obtained after 
injection of these bubbles in rats bearing pancreatic tumors and exposure of the tumor to 
ultrasound. The same strategy was recently used by Ting et al. [15] to prepare 1,3-
bis(chloroethyl)-1-nitrosurea (BCNU) loaded microbubbles. Focused ultrasound was used to 
locally implode BCNU carrying microbubbles at the blood brain barrier (BBB) of rats. This 
resulted in a significantly higher uptake of BCNU in glioma tumors implanted in the rats and 
a slower tumor progression when compared to BBB disruption with microbubbles and 
ultrasound co-administered with BCNU.  
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A serious drawback of electrostatic drug loading of microbubbles could be premature 
release of the drug in the body. Indeed, once injected in the bloodstream charged blood 
components like serum albumin can compete or interact with the charged microbubble shell. 
This can result in a release of the attached drug or in the formation of large aggregates 
which can block the vasculature [16]. Sirsi and colleagues also showed that charged 
microbubbles can influence circulation times by adhering nonspecifically to the vasculature 
close to the injection place. This can have a significant impact on the amount of 
microbubbles reaching the target tissue.  
3.1.2 Drug reservoirs. 
As an alternative, some research groups have tried to create a drug reservoir inside the 
microbubble. One example is the use of double emulsion techniques to obtain polymer 
coated oil–filled microcapsules [17]. Another technique, as described by Tartis et al [18], 
involves the incorporation of a drug-containing oil-phase within lipid-coated microbubbles. 
These oil filled microbubbles retain their responsiveness to ultrasound and can be 
destructed at higher ultrasound intensities thereby releasing their content. The fact that only 
lipid-soluble drugs can be incorporated however, limits the use of such systems.  
Another, more versatile method to prepare drug-loaded microbubbles, is the attachment of 
multiple drug reservoirs (i.e. drug loaded nanoparticles) to the microbubbles’ surface. The 
major benefit of this concept is that it creates a higher drug loading capacity, as plenty of 
small drug-filled pods are attached to the surface. Another advantage is that different types 
of therapeutics can become stored in microbubbles. Liposomes, for example, can be loaded 
with both hydrophilic and hydrophobic drugs and can carry larger molecules like pDNA, 
siRNA or mRNA [19]. Biotinylated lipid coated bubbles can be easily prepared by introducing 
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a phospholipid containing a PEG-biotin group into the microbubble shell. Such biotin 
containing bubbles can be incubated with avidin, enabling the subsequent attachment of 
biotinylated (drug containing) nanoparticles. Our group showed that this concept can be 
used to enhance the uptake and therapeutic efficiency of both small (DOX) [20] and high 
molecular weight drugs (pDNA, siRNA, mRNA) [21-23].  
Although avidin-biotin binding is an easy and straightforward method to obtain nanoparticle 
decorated microbubbles, it limits the in vivo application of nanoparticle loaded microbubbles 
due to the immunogenic nature of the avidin molecule [24]. Furthermore, the loading 
procedure requires several washing steps that influence microbubble stability and inter-
batch reproducibility. This stimulated us to design “self-assembling liposome loaded 
microbubbles” [25]. In this concept, maleimide functionalized liposomes (containing DOX) 
are mixed with a lipid solution containing dipalmitoylphosphatidylcholine (DPPC) and 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-N-[PDP(polyethylene glycol) (DSPE-PEG-SPDP) 
and covered with perfluorobutane gas. As shown in Figure 3 shaking of these vials in a high-
speed mixing device (CapmixTM) spontaneously results in the formation of self-assembled 
liposome loaded microbubbles. Note that in this way the liposomes become covalently 
bound to the microbubbles, in opposite to other methods that enable the attachment of 
nanoparticles like electrostatic loading or avidin-biotin approaches. 
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Figure 3: Schematic depiction of the production procedure of self-assembled liposome-
loaded microbubbles. Reprinted with permission from Elsevier (Geers et al. 2011a) [25]. 
An important question when using drug-loaded microbubbles remains whether a sufficient 
amount of drug can become incorporated in the microbubbles. As recently reviewed by 
Barenholz [26], the first clinical trials with liposomal DOX in humans reported a dosing 
between 25 and 50 mg/m2 [27], this corresponds with approximately 0.5-1 mg/kg. This 
implies that a dose of 40-80 mg should be administred to a normal 75 kg patient. One can 
wonder whether it is feasible to administer this dose to a patient when the drug is 
formulated as a microbubble dispsersion. According to our calculations (Geers et al. 2011a 
[25], lentacker et al. 2010 [20]) and the work performed by Tinkov et al [14,28] between 10 
and 40 µg of DOX can be loaded in 1 ml of bubble dispersion which allows us to suggest that 
liters of a bubble dispersion should be infused, which is practically impossible. Note that in 
ultrasound imaging with diagnostic bubbles, one is allowed to inject maximal 1 ml of bubble 
dispersion [2,29,30] per treatment. One can expect however, that using the self-assembled 
microbubbles the amount of bubbles needed for efficient treatment would be reduced. 
Indeed, we have shown that ultrasound assisted drug delivery can enhance the efficacy of 
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DOX, at least in vitro (Figure 4). We observed a stronger cytotoxicity of DOX, even at doses 
that did not show toxicity in the free form (which shows more cytotoxicity than liposomal 
DOX). Given the stronger effect of liposomal DOX loaded on microbubbles upon insonation, 
one could envisage that lower doses of DOX can be administered to obtain the same effect 
and thus a lower dispersion volume is needed. 
 
Figure 4: Cell viability experiments showing an increased cell killing efficiency of DOX when 
the drug was encapsulated in liposomes and bound to microbubbles, followed by ultrasound 
treatment. Reprinted with permission of Elsevier (Geers et al 2011a) [25]. 
We would like to note however that this issue is relevant only for small molecules. In the 
case of genetic drugs (like siRNA, pDNA and mRNA) the efficient delivery of a few strands 
should be enough to obtain sufficient therapeutic response.  
3.2  Ultrasound responsive liposomes (nanobubbles). 
A major disadvantage of microbubbles as drug carriers is their relatively large size (1-6 µm). 
Due to this feature, microbubbles have a rather short half-life, i.e. in the order of minutes 
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[19,31]. Upon injection such microbubbles will circulate a few times, but will inevitably get 
stuck in the lungs where gas exchange occurs. Consequently, microbubble-ultrasound 
triggered drug delivery will be mainly restricted to cardiovascular targets and to tumor 
endothelia. 
To solve this problem, several papers report on so-called nanobubbles [29,30], also named 
‘bubble liposomes’ [32], which are smaller than 1 µm, combining the benefits of a liposome 
(small size, long circulation time) with ultrasound responsiveness. These small bubbles are 
generally prepared by sonicating liposomes in the presence of fluorinated gases. With these 
nanobubbles successful delivery of pDNA, siRNA and coumarin [33] has been demonstrated 
both in in vitro and in vivo models.  
3.3 In situ generation of microbubbles from nanodroplets 
A very intelligent suggestion for circumventing the short half-life of drug-loaded 
microbubbles is the design of nanoscopic droplets based on perfluorocarbons with a 
relatively low boiling point (e.g. perfluoropentane or perfluorohexane). These so-called 
‘nanodroplets’ can convert into  their gaseous form upon ultrasound exposure. The 
advantage of the use of liquid perfluorocarbons  is that they can be emulsified in water when 
stabilized by an appropriate surfactant (e.g. pluronic, lipids) [34-36]. Such nanodroplets are 
typically smaller than 200 nm, which allows them to extravasate from the leaky tumor 
vasculature [37]. When the tumor tissue is subsequently treated with ultrasound, a liquid to 
gas phase transition occurs due to a local temperature increase in combination with the low 
pressure phase generated by the ultrasound [38]. As a consequence, ultrasound responsive 
microbubbles are formed in situ. 
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Alternatively, perfluorocarbons with a low boiling point can be encapsulated in inorganic 
mesoporous silica-nanoparticles which can incorporate various types of drugs as well 
[39][40]. Perfluorocarbon-drug-loaded silica-nanoparticles may well provide a solution for 
the different challenges we are facing with regard to drug-loaded ultrasound contrast agents, 
namely sufficient extravasation in tissues and high loading of (multiple) compounds. 
3.4. Targeted microbubbles for drug delivery. 
Recently there is growing interest in the use of ‘targeted microbubbles’ for diagnostic 
molecular imaging. Such microbubbles should be able to interact with molecules that 
become expressed in specific pathologies. In this case antibodies [41] or even nanobodies 
[42] are coupled to the surface of the bubbles, typically through avidin-biotin coupling [43]. 
Aptamers, nucleic acids that show affinity for specific molecules, can be used as targeting 
moieties as well [44]. Aptamer-loaded nanobubbles [45] have been described and show 
potential for targeting specific cell types. Clearly, targeted microbubbles can be of interest 
for drug-delivery as well as the amount of drug closely located near the target tissue may 
become enhanced [46].  
4 THERAPEUTIC MOIETIES BENEFITING FROM ULTRASOUND TRIGGERED 
DELIVERY  
The therapeutic moieties reported in the context of ultrasonic delivery can be divided in 
three different groups (Figure 5): (a) low molecular weight drugs like some anticancer drugs, 
(b) large biomolecules like genetic drugs and proteins and, finally, (c) drugs encapsulated in 
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nanoparticles. 
 
 
Figure 5: Schematic representation of different therapeutic moieties which can be delivered 
using microbubbles and ultrasound.  
Depending on its characteristics a drug can benefit from ultrasound triggered drug delivery 
differently, as ultrasound and microbubbles will either enhance the uptake of a molecule or 
particle that shows limited uptake or it will localize their bioavailablity . 
4.1 Small therapeutic molecules 
The “small therpautics” used in ultrasonic drug delivery studies are mostly antineoplastic 
drugs like DOX or Paclitaxel. Upon injection such low molecular weight drugs will distribute 
throughout the body and easily accumulate in different cell types, causing cytotoxic (side) 
effects. The most important reason why these drugs would benefit from ultrasonic drug 
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delivery is the fact that drug uptake would become limited to the ultrasound treated tissue. 
A more efficient localized delivery to the tumor can substantially reduce the required dose 
and lower side effects.  
4.2 Large therapeutic molecules 
Large molecules like nucleic acids (pDNA, siRNA, mRNA) and proteins are under investigation 
for ultrasonic delivery as well. Unlike small molecules these macromolecules show inefficient 
uptake in target tissues. As Figure 5 envisions, ultrasound mediated microbubble destruction 
can be used to locally permeablize cell membranes which should enhance the uptake of 
large molecules. 
The most important studies report on the delivery of genes into cells, in vitro and/or in vivo. 
Most studies involve pDNA, associated with a microbubble [47] or co-administred [48,49] 
with them. Due to its negative electrostatic loading pDNA will not penetrate into cells, but if 
it is located near a microbubble imploding in the vicinity of a cell it may profit from the 
temporal permeablization of the cell membrane (sonoporation) [50].  
4.3 Drugs encapsulated in nanoparticles  
Not only single molecules can benefit from ultrasonic delivery. Several publications have 
shown that microbubbles and ultrasound can be used to improve the extravasation of a 
variety of nanoparticles that can be loaded with a drug or have a therapeutic effect 
themselves. PLGA nanoparticles [51], magnetic nanoparticles [52], liposomes and lipoplexes 
[53], gold nanoparticles and silica nanoparticles [54] were used in combination with 
microbubbles and ultrasound. Through encapsulating the drug molecules in nanoscopic 
particles they become well protected against degradation, which is a major challenge, 
especially for biological drugs. 
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5 INFLUENCE OF ULTRASOUND PARAMETERS ON DRUG-DELIVERY 
EFFICIENCY 
As schematically shown in Figure 6, an ultrasound wave basically has 3 characteristics that 
may play a role in ultrasonic drug delivery: (a) the number of cycles per ultrasound pulse, (b) 
the peak negative pressure and (c) the frequency. In most ultrasonic drug delivery related 
reports ultrasound waves with a frequency of around 1 Mhz are used, the major reason 
being that the frequency which allows the microbubbles to respond upon ultrasound 
exposure indeed depends on the size of the bubbles which, in most studies, is between 1 
and 3 µm.  
 
Figure 6: Schematic representation of the ultrasound pulse, cycle and peak negative pressure 
of an ultrasound wave. 
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In contrast to frequency, the variety of ultrasound pressures used in different studies is 
striking. At higher acoustic pressures (above a threshold of approximately 500 kPa [55]), the 
microbubbles will highly likely show inertial cavitation. This may result in the formation of 
shock waves and micro-jets [56,57]. Different studies report that such effects may porate 
cell membranes [55,58-60] and may facilitate the delivery of nanoparticles into the 
cytoplasm of cells [22,61]. In other studies lower acoustic pressures are used. Under these 
conditions, the bubble will “gently” oscillate and disturb its surroundings. If a microbubble is 
located near the cell membrane, these gentle oscillations may induce cell membrane 
instabilities which may stimulate endocytosis [55,62]. 
Another important variable if one compares ultrasound settings used in different studies, is 
the number of acoustic cycles (i.e. the number of acoustic oscillations per ultrasound pulse) 
applied to the samples. As shown by Mannaris et al [63], bubbles can oscillate at lower 
pressures when up to 100 cycles are used. However, when more cycles are applied 
combined with higher pressures, the bubbles become instantaneously destroyed. 
Subsequently, under such conditions one does no longer study microbubble related effects 
on drug delivery but rather effects from ultrasound forces. These forces may play an 
important role in in vivo drug and gene delivery, although this still has not been investigated 
in detail. Studies on ultrasonic drug delivery were indeed performed, reporting the use of 
10000 cycles and high acoustic pressure [64]. This study clearly shows these settings do have 
an effect on drug delivery and the effects generated will not be caused by imploding 
microbubbles.  
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6 PRECLINICAL EVIDENCE 
Searching for in vivo evidence for ultrasonic drug delivery with microbubbles, a difference is 
observed between the number of studies reporting the co-administration approach (i.e. the 
co-administration of drugs and microbubbles), and the number of reports in which drug-
loaded microbubbles are studied. 
There is clear preclinical evidence available in the literature with regard to the co-
administration approach. Many studies, as e.g. performed by Hynynen, McDannold and co-
workers, show enhanced drug delivery after injection of diagnostic microbubbles (Sonovue® 
or Definity®) and applying ultrasound allowing bubbles to implode at the target site. For 
example, enhanced drug [65] or Magnetic Resonance (MR) contrast-agent [66] delivery into 
the brain of rats has been shown. In these brain delivery studies, a transient disruption of 
the Blood Brain Barrier (BBB), induced by microbubble implosion has been reported. An 
enhanced delivery of Evans blue in muscles [67] has been shown as well following the co-
administration approach. The progress in this particular field has been reviewed by 
Vykhodtseva et al [68].  
The number of in vivo studies with drug loaded microbubbles is rather limited, is probably 
due to the fact that ‘loading microbubbels with drugs’ is a recent strategy in ultrasonic drug 
delivery. Indeed, while in co-administration approved commercial (clinically used) 
microbubbles can be used, custom-made (still often poorly characterized) drug loaded 
microbubbles need to be designed. Rapoport et al showed reduced tumor growth with 
Paclitaxel-loaded nanodroplets [69]. Tinkov [28] showed enhanced DOX-uptake in tumors 
with DOX-loaded microbubbles. Accoustically active pDNA bubble liposomes resulted in 
enhanced gene transfection in the mouse abdomen [70]. Finally, Müller et al [71] reported 
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an improved gene transduction in the heart of rats using microbubbles with adeno-
associated viral vectors electrostatically attached to the surface of the bubbles.  
7 EMERGING CONCEPTS AND APPLICATIONS 
7.1 Theranostics 
An elegant new approach would be the use of drug-loaded microbubbles as a theranostic 
tool. Theranostics is an emerging field that focuses on the combination of drug therapy and 
diagnosis via medical imaging techniques (e.g.: MRI, ultrasound) [72,73]. It involves the use 
of agents that are able (a) to visualize a specific pathological process and (b) simultaneously 
deliver a drug at this site. Kiessling et al[74] reported recently on the current status of 
different preclinical and clinical theranostic applications. It would be a breakthrough if one 
could design a drug loaded microbubble which specifically detects pathophysiological 
processes and which delivers its drug at the site where a diagnostic signal is observed. As 
shown above, various types of antibody loaded microbubbles have been described, however, 
so far targeted drug loaded microbubbles have not been reported.  
Note that microbubbles can be used as contrast agents in Magnetic Resonance Imaging (MRI) 
as well, as they can be loaded with FeO2
7.2 Temporal window upon sonoporation and two-step delivery protocols. 
 [75] or other magnetic nanoparticles providing a 
magnetic contrast in MRI. Intrinsically microbubbles can be visualized via 19F-MRI as well 
[76].  
Several research groups have demonstrated the existence of cell membrane pores upon 
applying ultrasound lasting in the order of seconds to minutes [50,60,77,78]. However, 
Yudina and colleagues recently claimed pore opening lasting up to 24h [79]. This was 
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evidenced by evaluating the uptake of the small molecule Sytox® Green as a function of time 
in sonoporated glioma cells. Although a further confirmation of the observations of Yudina 
et al would be useful, these findings open up new perspectives for ultrasonic drug delivery . 
The same group also proposed a two-step delivery protocol combining the benefits of 
temperature sensitive liposomes (being liposomes that release their content at 
temperatures around 41°C) and sonoporation [80]. A proof of concept paper was published 
using TO-PRO-3 loaded thermosensitive liposomes and diagnostic microbubbles. Upon 
heating by high intensity focused ultrasound (HIFU), TO-PRO-3 became released from the 
temperature sensitive liposomes while the membrane permeabilization promoted the 
uptake of TO-PRO-3 in the cancer cells. Based upon their findings that drug uptake can last 
for several hours after sonoporation, the authors also suggested that it could be even more 
advantageous first to sonoporate the tissue (taking advantage of the temporal window), 
followed by different applications of the nanoparticles. 
7.3 Stem cell therapy 
There are indications that stem cell therapy can be used to repair infarcted cardiac tissue 
and even improve cardiac function. However, current clinical studies are not convincing as 
only a small fraction of the injected stem cells is able to reach the ischemic heart region [81]. 
Recently, several research groups have shown that a combination of microbubbles and 
ultrasound [82-84] or focused ultrasound only [48] can be applied to enhance the migration 
or extravasation of stem cells. This is particularly interesting to enhance the homing of 
mesenchymal stem cells to ischemic heart tissue. An important consequence of the 
microbubble implosions is the creation of a local inflammation response and an enhanced 
expression of inflammatory cytokines (e.g. SDF-1) and adhesion receptors (VCAM-1). It has 
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been demonstrated that SDF-1 is a crucial factor to mediate the homing of stem cells to 
myocardial tissue [85] and that VCAM-1 is involved in the adhesion of stem cells to the 
damaged endothelium. These results indicate that a pre-treatment of the ischemic tissue 
with imploding microbubbles could be a very promising strategy to improve the outcome of 
stem cell therapy for myocardial infarctions.  
7.4 Cancer vaccination  
Another interesting emerging application is the use of microbubbles and ultrasound for 
cancer vaccination. Cancer vaccination strategies nowadays relies upon the in vitro 
manipulation of antigen-presenting cells (APC) like dendritic cells (DCs). APCs are able to 
capture and process antigens and present them to CD4+ or CD8+ T-cells. Activated T-cells are 
responsible for cellular immunity and can be used to eliminate cancerous cell lines before 
they can do any harm. In 2009, Un and colleagues [86] were the first to use “bubble 
liposomes” and ultrasound to pulse DCs with the model-antigen ovalbumin. 
Recently, our group showed that nanoparticle loaded microbubbles (mRNA-lipoplex loaded 
microbubbles) can be used to transfect DC’s as well, resulting in a significant expression of 
reporter genes. Sonoporation of mouse DCs leads to a slight shift in maturation status of DCs 
which could be interesting to obtain an efficient T-cell response. The concept of 
sonoporation based vaccination is shown in Figure 7. 
The idea of microbubble and ultrasound induced vaccination is attractive as it has been 
shown that vaccination in the lymph nodes (intranodal vaccination) leads to a stronger 
immune response [87]. Sonoporation could be a valuable alternative to ex vivo 
electroporation as it could enable the direct intranodal transfection of DCs in vivo, thereby 
circumventing the expensive and time-consuming procedure of ex vivo transfection. In this 
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regard it has been shown that microbubbles are able to migrate to the lymph nodes after 
subcutaneous injection, a technique which is currently under investigation for sentinel 
lymph node detection [88]. 
 
Figure 7: Schematic representation of the concept of ultrasound and microbubble enhanced 
cancer vaccination. Reprinted with permission from Elsevier (De Temmerman et al [21]). 
8 PERSPECTIVES  
Generally, we can conclude that ultrasonic drug delivery becomes an increasingly attractive 
technique in medicine, as reflected by the growing number of research groups being active 
in this field.  
We need to emphasize, however, that the full potential of this technique is not yet met: (a) 
microbubble design can be further explored and perfected for new emerging applications 
like vaccination or theranostics; (b) there is no concensus on the exact ultrasound settings to 
be used in drug delivery and (c) new insights in sonoporation and cellular mechanisms (like 
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the temporal window and two-steps delivery) need to be further explored to allow optimal 
use of the biological implications of ultrasonic drug delivery. 
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